Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea

INTRODUCTION: SB2 is a biosimilar of infliximab (IFX), which is approved for rheumatoid arthritis (RA), ankylosing spondylitis (AS), adult and pediatric Crohn’s disease (CD), adult and pediatric ulcerative colitis (UC), psoriatic arthritis (PsA), and plaque psoriasis (PsO). The drug approval process...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong W., Lee, Yousun, Kim, Geuntae, Kim, Sang H., Cho, Dae H., Choi, Jeongmin, Kwon, Yong H., Park, Younjin, Choi, Wooree, Park, Dong I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989004/
https://www.ncbi.nlm.nih.gov/pubmed/36624354
http://dx.doi.org/10.1007/s12325-022-02404-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989004/
https://www.ncbi.nlm.nih.gov/pubmed/36624354
http://dx.doi.org/10.1007/s12325-022-02404-x

Ejemplares similares